GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » eFFECTOR Therapeutics Inc (OTCPK:EFTR) » Definitions » FCF Yield %

EFTR (eFFECTOR Therapeutics) FCF Yield % : -2,927,500.00 (As of Mar. 29, 2025)


View and export this data going back to 2021. Start your Free Trial

What is eFFECTOR Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, eFFECTOR Therapeutics's Trailing 12-Month Free Cash Flow is $-29.28 Mil, and Market Cap is $0.00 Mil. Therefore, eFFECTOR Therapeutics's FCF Yield % for today is -2,927,500.00%.

The historical rank and industry rank for eFFECTOR Therapeutics's FCF Yield % or its related term are showing as below:

EFTR' s FCF Yield % Range Over the Past 10 Years
Min: -34056039.85   Med: -247.74   Max: -1.7
Current: -2927500


During the past 4 years, the highest FCF Yield % of eFFECTOR Therapeutics was -1.70%. The lowest was -34056039.85%. And the median was -247.74%.

EFTR's FCF Yield % is ranked worse than
100% of 1500 companies
in the Biotechnology industry
Industry Median: -14.52 vs EFTR: -2927500.00

eFFECTOR Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.


eFFECTOR Therapeutics FCF Yield % Historical Data

The historical data trend for eFFECTOR Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

eFFECTOR Therapeutics FCF Yield % Chart

eFFECTOR Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
FCF Yield %
- -7.45 -146.32 -85.05

eFFECTOR Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -204.62 -67.56 -82.76 -64.49 -51.85

Competitive Comparison of eFFECTOR Therapeutics's FCF Yield %

For the Biotechnology subindustry, eFFECTOR Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


eFFECTOR Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, eFFECTOR Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where eFFECTOR Therapeutics's FCF Yield % falls into.


;
;

eFFECTOR Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

eFFECTOR Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-29.647 / 34.856355
=-85.05%

eFFECTOR Therapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-7.278 * 4 / 56.14978
=-51.85%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


eFFECTOR Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


eFFECTOR Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of eFFECTOR Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


eFFECTOR Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
142 North Cedros Avenue, Suite B, Solana Beach, CA, USA, 92075
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).
Executives
Sr One Capital Fund I Aggregator Lp 10 percent owner C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Christopher B Ehrlich director, 10 percent owner, officer: Chief Executive Officer 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Mayank Gandhi officer: Chief Business Officer 628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Douglas J Warner officer: Chief Medical Officer C/O EFFECTOR THERAPEUTICS, INC., 142 NORTH CEDROS AVENUE, SUITE B, SOLANA BEACH CA 92075
Presidio Management Group X Llc 10 percent owner 2735 SAND HILL ROAD, MENLO PARK CA 94025
Carlyle Group Inc. 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Carlyle Genesis Uk Llc 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004
Carlyle Investment Management Llc 10 percent owner 1001 PENNSYLVANIA AVE. N.W., WASHINGTON DC 20004
Carlyle Holdings I L.p. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Carlyle Holdings I Gp Inc. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Tc Group, Llc 10 percent owner C/O CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE NW SUITE 220 S, WASHINGTON DC 20004
Cg Subsidiary Holdings L.l.c. 10 percent owner C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Carlyle Holdings I Gp Sub L.l.c. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Gallagher Brian M. Jr. director, 10 percent owner C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139
Stephen T Worland director, officer: President and Chief Executive 9050 CAMINO SANTA FE, SAN DIEGO CA 92121